Richard A. Heyman, Director at Oric Pharmaceuticals, Inc. (ORIC), sold 300 shares at $12.00 ($4K) on 2026-07-06, disclosed to the SEC on 2026-07-08.
Scheduled sale ($4k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| ELVN | SELL | 2026-01-22 | $33K | — | Filing → |
| ORIC | SELL | 2026-01-20 | $80K | — | Filing → |
| ELVN | SELL | 2026-01-12 | $656K | — | Filing → |